Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by FREDRICK B HAGEMEISTER and MARIA A RODRIGUEZ.
FREDRICK B HAGEMEISTER
Connection Strength
2.563
MARIA A RODRIGUEZ
  1. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8.
    View in: PubMed
    Score: 0.124
  2. Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):384-91.
    View in: PubMed
    Score: 0.120
  3. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(?) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol. 2013 Sep; 162(5):631-8.
    View in: PubMed
    Score: 0.114
  4. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec; 54(12):2631-8.
    View in: PubMed
    Score: 0.113
  5. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):15-8.
    View in: PubMed
    Score: 0.109
  6. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol. 1990 Dec; 17(6 Suppl 10):34-8; discussion 38-40.
    View in: PubMed
    Score: 0.095
  7. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 01; 23(4):667-75.
    View in: PubMed
    Score: 0.063
  8. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep. 2003 Sep-Oct; 10(5):1513-8.
    View in: PubMed
    Score: 0.058
  9. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol. 2000; 11 Suppl 1:137-40.
    View in: PubMed
    Score: 0.045
  10. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24.
    View in: PubMed
    Score: 0.044
  11. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood. 1999 Jun 01; 93(11):3632-6.
    View in: PubMed
    Score: 0.043
  12. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999 May 01; 93(9):3081-7.
    View in: PubMed
    Score: 0.043
  13. The clinical significance of molecular response in indolent follicular lymphomas. Blood. 1998 Apr 15; 91(8):2955-60.
    View in: PubMed
    Score: 0.040
  14. Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients. Leuk Lymphoma. 1998 Jan; 28(3-4):295-306.
    View in: PubMed
    Score: 0.039
  15. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol. 1997 Dec; 15(12):3488-95.
    View in: PubMed
    Score: 0.039
  16. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995 Jul; 13(7):1734-41.
    View in: PubMed
    Score: 0.033
  17. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995 Jul; 6(6):609-11.
    View in: PubMed
    Score: 0.033
  18. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.
    View in: PubMed
    Score: 0.032
  19. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82.
    View in: PubMed
    Score: 0.032
  20. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun; 169(6):814-23.
    View in: PubMed
    Score: 0.032
  21. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84.
    View in: PubMed
    Score: 0.031
  22. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901.
    View in: PubMed
    Score: 0.030
  23. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol. 1994 Apr; 31(2 Suppl 3):36-43.
    View in: PubMed
    Score: 0.030
  24. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014 Apr; 165(1):112-6.
    View in: PubMed
    Score: 0.029
  25. Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas. Ann Oncol. 1994; 5 Suppl 2:41-6.
    View in: PubMed
    Score: 0.029
  26. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol. 1994; 5 Suppl 2:59-63.
    View in: PubMed
    Score: 0.029
  27. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.
    View in: PubMed
    Score: 0.029
  28. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol. 1993 Feb; 4(2):125-31.
    View in: PubMed
    Score: 0.028
  29. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol. 1992 Nov; 3(9):711-7.
    View in: PubMed
    Score: 0.027
  30. NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis. Ann Oncol. 1992 Sep; 3 Suppl 4:87-90.
    View in: PubMed
    Score: 0.027
  31. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8.
    View in: PubMed
    Score: 0.026
  32. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk Lymphoma. 2012 May; 53(5):801-6.
    View in: PubMed
    Score: 0.026
  33. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma. 2012 Jan; 53(1):50-6.
    View in: PubMed
    Score: 0.025
  34. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5.
    View in: PubMed
    Score: 0.025
  35. Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy. Blood. 1991 Mar 01; 77(5):942-7.
    View in: PubMed
    Score: 0.024
  36. Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's disease. Ann Oncol. 1991 Jan; 2(1):25-31.
    View in: PubMed
    Score: 0.024
  37. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Jul; 150(2):200-8.
    View in: PubMed
    Score: 0.023
  38. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 01; 27(31):5213-8.
    View in: PubMed
    Score: 0.022
  39. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008 Nov 15; 113(10):2734-41.
    View in: PubMed
    Score: 0.021
  40. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008 Nov; 143(3):355-60.
    View in: PubMed
    Score: 0.020
  41. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol. 1988 Apr; 25(2 Suppl 2):47-50.
    View in: PubMed
    Score: 0.020
  42. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol. 2008 Mar; 19(3):553-9.
    View in: PubMed
    Score: 0.019
  43. Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature. Am J Hematol. 2007 Aug; 82(8):725-8.
    View in: PubMed
    Score: 0.019
  44. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5.
    View in: PubMed
    Score: 0.019
  45. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Feb; 136(3):439-47.
    View in: PubMed
    Score: 0.018
  46. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006 Nov 15; 194(10):1394-7.
    View in: PubMed
    Score: 0.018
  47. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Sep; 47(9):1818-21.
    View in: PubMed
    Score: 0.018
  48. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006 Apr 01; 24(10):1582-9.
    View in: PubMed
    Score: 0.017
  49. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Mar; 47(3):481-5.
    View in: PubMed
    Score: 0.017
  50. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 01; 23(28):7013-23.
    View in: PubMed
    Score: 0.017
  51. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer. 2005 Jul 15; 104(2):345-53.
    View in: PubMed
    Score: 0.016
  52. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102.
    View in: PubMed
    Score: 0.015
  53. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res. 2004 Aug 15; 10(16):5432-8.
    View in: PubMed
    Score: 0.015
  54. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23.
    View in: PubMed
    Score: 0.015
  55. Thalidomide for patients with recurrent lymphoma. Cancer. 2004 Mar 15; 100(6):1186-9.
    View in: PubMed
    Score: 0.015
  56. Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol. 2004 Feb; 27(1):73-80.
    View in: PubMed
    Score: 0.015
  57. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003 Jul 15; 98(2):310-4.
    View in: PubMed
    Score: 0.014
  58. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003 Jun 01; 21(11):2115-22.
    View in: PubMed
    Score: 0.014
  59. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003 Feb 01; 97(3):586-91.
    View in: PubMed
    Score: 0.014
  60. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Jan 01; 55(1):36-43.
    View in: PubMed
    Score: 0.014
  61. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood. 2002 Dec 15; 100(13):4351-7.
    View in: PubMed
    Score: 0.013
  62. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park). 2002 Aug; 16(8 Suppl 7):27-31.
    View in: PubMed
    Score: 0.013
  63. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2001 Jul; 12(7):923-7.
    View in: PubMed
    Score: 0.012
  64. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma. 2001 Jun; 2(1):40-6.
    View in: PubMed
    Score: 0.012
  65. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma. 2001 May; 41(5-6):535-44.
    View in: PubMed
    Score: 0.012
  66. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol. 2001 Jan 15; 19(2):398-405.
    View in: PubMed
    Score: 0.012
  67. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000 Dec; 27(6 Suppl 12):37-41.
    View in: PubMed
    Score: 0.012
  68. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol. 2000 Dec; 11(12):1551-6.
    View in: PubMed
    Score: 0.012
  69. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma. 2000 Oct; 39(3-4):291-9.
    View in: PubMed
    Score: 0.012
  70. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000 Sep; 39(1-2):77-85.
    View in: PubMed
    Score: 0.012
  71. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20.
    View in: PubMed
    Score: 0.012
  72. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000 Jan; 11(1):69-72.
    View in: PubMed
    Score: 0.011
  73. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999 Jul 20; 131(2):88-95.
    View in: PubMed
    Score: 0.011
  74. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999 Apr; 10(4):433-40.
    View in: PubMed
    Score: 0.011
  75. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood. 1999 Apr 01; 93(7):2202-7.
    View in: PubMed
    Score: 0.011
  76. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Invest New Drugs. 1999; 17(2):187-92.
    View in: PubMed
    Score: 0.010
  77. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec; 16(12):3803-9.
    View in: PubMed
    Score: 0.010
  78. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Br J Haematol. 1998 Dec; 103(3):678-83.
    View in: PubMed
    Score: 0.010
  79. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma. 1998 Dec; 32(1-2):97-106.
    View in: PubMed
    Score: 0.010
  80. Stage I Hodgkin disease: radiation therapy and chemotherapy at the University of Texas M. D. Anderson Cancer Center, 1996-1997. Radiology. 1998 Sep; 208(3):739-47.
    View in: PubMed
    Score: 0.010
  81. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma. Ann Oncol. 1998 May; 9(5):511-8.
    View in: PubMed
    Score: 0.010
  82. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998 Feb 15; 91(4):1178-84.
    View in: PubMed
    Score: 0.010
  83. Hodgkin's disease: correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):377-86.
    View in: PubMed
    Score: 0.010
  84. Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys. 1997 Oct 01; 39(3):609-16.
    View in: PubMed
    Score: 0.010
  85. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1997 Jun; 26(1-2):77-82.
    View in: PubMed
    Score: 0.009
  86. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol. 1997 Feb; 96(2):328-32.
    View in: PubMed
    Score: 0.009
  87. Paclitaxel (Taxol) for the treatment of lymphoma. Ann Oncol. 1997; 8 Suppl 1:129-31.
    View in: PubMed
    Score: 0.009
  88. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol. 1996 Feb; 14(2):543-8.
    View in: PubMed
    Score: 0.009
  89. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol. 1996 Feb; 7(2):157-63.
    View in: PubMed
    Score: 0.009
  90. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1996 Jan; 14(1):233-9.
    View in: PubMed
    Score: 0.008
  91. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma. 1995 Jun; 18(1-2):87-92.
    View in: PubMed
    Score: 0.008
  92. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1995 Mar; 13(3):583-7.
    View in: PubMed
    Score: 0.008
  93. Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study. Clin Oncol (R Coll Radiol). 1995; 7(5):300-3.
    View in: PubMed
    Score: 0.008
  94. Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys. 1995 Jan 01; 31(1):3-11.
    View in: PubMed
    Score: 0.008
  95. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol. 1994 Nov; 5(9):847-9.
    View in: PubMed
    Score: 0.008
  96. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994 Jun; 12(6):1169-76.
    View in: PubMed
    Score: 0.008
  97. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. Cancer. 1994 May 01; 73(9):2408-16.
    View in: PubMed
    Score: 0.008
  98. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol. 1994 Mar; 12(3):575-9.
    View in: PubMed
    Score: 0.007
  99. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Invest New Drugs. 1994; 12(3):217-22.
    View in: PubMed
    Score: 0.007
  100. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol. 1994; 5 Suppl 2:73-7.
    View in: PubMed
    Score: 0.007
  101. Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. Ann Oncol. 1994; 5 Suppl 2:97-100.
    View in: PubMed
    Score: 0.007
  102. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol. 1993 Mar; 4(3):205-11.
    View in: PubMed
    Score: 0.007
  103. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992 May; 10(5):790-4.
    View in: PubMed
    Score: 0.007
  104. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1992; 23(2):407-12.
    View in: PubMed
    Score: 0.006
  105. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med. 1991 May 15; 114(10):855-60.
    View in: PubMed
    Score: 0.006
  106. Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol. 1991 Feb; 9(2):236-42.
    View in: PubMed
    Score: 0.006
  107. Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol. 1990 Apr; 8(4):615-22.
    View in: PubMed
    Score: 0.006
  108. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989 Oct; 7(10):1518-27.
    View in: PubMed
    Score: 0.005
  109. Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med. 1989 Aug; 87(2):167-72.
    View in: PubMed
    Score: 0.005
  110. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst. 1988 Nov 02; 80(17):1408-12.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.